• Contact us
  • Customer support
  • Login
  • Home
  • Technology
    • Introduction to Ex Vivo Lung Perfusion
    • The Ex Vivo Lung Perfusion Process
    • Clinical
    • Protocols
    • Starting your clinical EVLP program
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
    • Training and workshops
    • Patents
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • STEEN Solution™
    • PERFADEX® Plus
    • XVIVO
      Organ Chamber™
    • XVIVO
      Lung Cannula Set™
    • Instruction for Use
  • Knowledge
    • NOVEL Lung Trial
    • Literature
    • Insights
  • Media
    • Videos
    • Webinars
    • Establishing a successful EVLP program
  • About us
    • About XVIVO
    • History
    • Our market
    • News
    • Career
    • Working at XVIVO
  • Corporate
    • Corporate
    • The share
      • Info
      • Ownership structure
      • Insiders (PDMRs)
    • Press releases
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports
    • Financial reports – ESEF
    • Prospectus and material offerings
      • Material offerings
      • Prospectus
    • Financial presentations
      • Capital Markets Day
      • Earnings calls
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
      • Corporate Governance Reports
    • Analyst Coverage
    • Code of Conduct
    • Environmental Policy
    • Code of Conduct for Suppliers
    • Privacy policy
    • Contact us
    • Subscribe
    • Thank you
    • Error
XVIVO
  • Contact us
  • Customer support
  • Home
  • Technology
    • Introduction to Ex Vivo Lung Perfusion
    • The Ex Vivo Lung Perfusion Process
    • Clinical
    • Protocols
    • Starting your clinical EVLP program
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
    • Training and workshops
    • Patents
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • STEEN Solution™
    • PERFADEX® Plus
    • XVIVO
      Organ Chamber™
    • XVIVO
      Lung Cannula Set™
    • Instruction for Use
  • Knowledge
    • NOVEL Lung Trial
    • Literature
    • Insights
  • Media
    • Videos
    • Webinars
    • Establishing a successful EVLP program
  • About us
    • About XVIVO
    • History
    • Our market
    • News
    • Career
    • Working at XVIVO
  • Corporate
    • Corporate
    • The share
      • Info
      • Ownership structure
      • Insiders (PDMRs)
    • Press releases
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports
    • Financial reports – ESEF
    • Prospectus and material offerings
      • Material offerings
      • Prospectus
    • Financial presentations
      • Capital Markets Day
      • Earnings calls
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
      • Corporate Governance Reports
    • Analyst Coverage
    • Code of Conduct
    • Environmental Policy
    • Code of Conduct for Suppliers
    • Privacy policy
    • Contact us
    • Subscribe
    • Thank you
    • Error
  • Corporate
  • The share
    • Info
    • Ownership structure
    • Insiders (PDMRs)
  • Press releases
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
  • Financial calendar
  • Financial reports
  • Financial reports – ESEF
  • Prospectus and material offerings
    • Material offerings
    • Prospectus
  • Financial presentations
    • Capital Markets Day
    • Earnings calls
  • Corporate governance
    • Article of Association
    • General meetings
    • Board of Directors
    • Senior Management
    • Auditors
    • Board Committees
    • Board and Senior Management share holdings
    • Guidelines for remuneration
    • Nomination Committee
    • Corporate Governance Reports
  • Analyst Coverage
  • Code of Conduct
  • Environmental Policy
  • Code of Conduct for Suppliers
  • Privacy policy
  • Contact us
  • Subscribe
  • Thank you
  • Error

Financial reports

Filter:
  • All
  • Interim reports
  • Annual Reports

2022

  • 2023-01-26Year-end ReportQ42022
  • 2023-01-26BokslutskommunikéQ42022
  • 2022-10-27KvartalsrapportQ32022
  • 2022-10-27Interim ReportQ32022
  • 2022-07-13KvartalsrapportQ22022
  • 2022-07-13Interim ReportQ22022
  • 2022-04-25KvartalsrapportQ12022
  • 2022-04-25Interim ReportQ12022

2021

  • 2022-04-04Annual Report2021
  • 2022-04-04Årsredovisning2021
  • 2022-01-27Year-end ReportQ42021
  • 2022-01-27BokslutskommunikéQ42021
  • 2021-10-21Interim ReportQ32021
  • 2021-10-21KvartalsrapportQ32021
  • 2021-07-13KvartalsrapportQ22021
  • 2021-07-13Interim ReportQ22021
  • 2021-04-21KvartalsrapportQ12021
  • 2021-04-21Interim ReportQ12021

2020

  • 2021-03-29Årsredovisning2020
  • 2021-03-29Annual Report2020
  • 2021-01-28BokslutskommunikéQ42020
  • 2021-01-28Year-end ReportQ42020
  • 2020-10-23KvartalsrapportQ32020
  • 2020-10-23Interim ReportQ32020
  • 2020-07-10Interim ReportQ22020
  • 2020-07-10KvartalsrapportQ22020
  • 2020-04-09Interim ReportQ12020
  • 2020-04-09KvartalsrapportQ12020

2019

  • 2020-03-09Årsredovisning2019
  • 2020-03-09Annual Report2019
  • 2020-01-30Year-end ReportQ42019
  • 2020-01-30BokslutskommunikéQ42019
  • 2019-10-24Interim ReportQ32019
  • 2019-10-24KvartalsrapportQ32019
  • 2019-07-12Interim ReportQ22019
  • 2019-07-12KvartalsrapportQ22019
  • 2019-04-24KvartalsrapportQ12019
  • 2019-04-24Interim ReportQ12019

2018

  • 2019-04-02Annual Report2018
  • 2019-04-02Årsredovisning2018
  • 2019-02-08BokslutskommunikéQ42018
  • 2019-02-08Year-end ReportQ42018
  • 2018-10-26KvartalsrapportQ32018
  • 2018-10-26Interim ReportQ32018
  • 2018-07-20KvartalsrapportQ22018
  • 2018-07-20Interim ReportQ22018
  • 2018-04-26Interim ReportQ12018
  • 2018-04-26KvartalsrapportQ12018

2017

  • 2018-04-04Årsredovisning2017
  • 2018-02-09BokslutskommunikéQ42017
  • 2018-02-09Year-end ReportQ42017
  • 2017-10-27Interim ReportQ32017
  • 2017-10-27KvartalsrapportQ32017
  • 2017-07-14Interim ReportQ22017
  • 2017-07-14KvartalsrapportQ22017
  • 2017-04-25Interim ReportQ12017
  • 2017-04-25KvartalsrapportQ12017

2016

  • 2017-04-04Årsredovisning2016
  • 2017-02-08Year-end ReportQ42016
  • 2017-02-08BokslutskommunikéQ42016
  • 2016-10-27Interim ReportQ32016
  • 2016-10-27KvartalsrapportQ32016
  • 2016-07-15Interim ReportQ22016
  • 2016-07-15KvartalsrapportQ22016
  • 2016-04-26Interim ReportQ12016
  • 2016-04-26KvartalsrapportQ12016

2015

  • 2016-04-11Årsredovisning2015
  • 2016-02-04Year-end ReportQ42015
  • 2016-02-04BokslutskommunikéQ42015
  • 2015-10-23Interim ReportQ32015
  • 2015-10-23KvartalsrapportQ32015
  • 2015-08-13Interim ReportQ22015
  • 2015-08-13KvartalsrapportQ22015
  • 2015-04-22KvartalsrapportQ12015
  • 2015-04-22Interim ReportQ12015

2014

  • 2015-03-31Årsredovisning2014
  • 2015-02-05Year-end ReportQ42014
  • 2015-02-05BokslutskommunikéQ42014
  • 2014-10-24Interim ReportQ32014
  • 2014-10-24KvartalsrapportQ32014
  • 2014-08-13Interim ReportQ22014
  • 2014-08-13KvartalsrapportQ22014
  • 2014-04-23Interim ReportQ12014
  • 2014-04-23KvartalsrapportQ12014

2013

  • 2014-04-07Årsredovisning2013
  • 2014-02-07Year-end ReportQ42013
  • 2014-02-07BokslutskommunikéQ42013
  • 2013-11-07KvartalsrapportQ32013
  • 2013-11-07Interim ReportQ32013
  • 2013-07-11KvartalsrapportQ22013
  • 2013-07-11Interim ReportQ22013
  • 2013-04-19Interim ReportQ12013
  • 2013-04-19KvartalsrapportQ12013

2012

  • 2013-04-15Årsredovisning2012
  • 2013-02-19Year-end ReportQ42012
  • 2013-02-19BokslutskommunikéQ42012
  • 2012-11-01KvartalsrapportQ32012
  • 2012-11-01Interim ReportQ32012
About us

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives.
Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine.
XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on three continents. The company is listed on Nasdaq.

Contact

Swedish Office
XVIVO Perfusion AB
Box 53015
SE-400 14 Göteborg
Sweden

Phone: +46 31 788 21 50
Fax: +46 31 788 21 69
info@xvivogroup.com

 

Report a violations or breach here: Whistleblower

  • Home
  • Technology
  • Products
  • Knowledge
  • Media
  • About us
  • Corporate

Copyright © 2023 XVIVO. All rights reserved.

Design mkmedia
To top

We use cookies to improve the user experience on XVIVO. Read more about Cookies

Approve